# Cd47靶向治疗市场

> CD47靶向治疗市场研究报告：按治疗领域（肿瘤学、自身免疫疾病、传染病、血液肿瘤）、按作用机制（单克隆抗体、小分子抑制剂、联合疗法）、按给药途径（静脉注射、皮下、口服、肌肉注射）、按最终用户（医院、专科诊所、研究机构）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 增长前景与行业预测2025至2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 22.89%
- **2024:** $ 2.41 Billion
- **2025:** $ 2.96 Billion
- **2035:** $ 23.3 Billion
- **Key Players:** Companies such Forty Seven Inc (US), Gilead Sciences Inc (US), Bristol-Myers Squibb Company (US), AstraZeneca PLC (GB), Novartis AG (CH), Merck & Co Inc (US), Amgen Inc (US), CureVac AG (DE), Zymeworks Inc (CA) are some of the major participants in the global market.

**Report ID:** MRFR/HC/38233-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/cd47-targeting-therapeutics-market-40260

---

## Market Summary

## **Global CD47 Targeting Therapeutics Market Overview**

As per MRFR analysis, the CD47 Targeting Therapeutics Market Size was estimated at 2.41 (USD Billion) in 2024. The CD47 Targeting Therapeutics Market Industry is expected to grow from 2.97 (USD Billion) in 2025 to 18.96 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 22.89% during the forecast period (2025 - 2034).

### **Key CD47 Targeting Therapeutics Market Trends Highlighted**

The CD47 Targeting Therapeutics Market is experiencing significant growth driven by the increasing prevalence of cancer and advancements in immunotherapy. CD47, known as the "don't eat me" signal, allows cancer cells to evade immune detection. As researchers uncover more about the role of CD47 in tumor progression, there is a growing interest in developing therapies that inhibit this pathway.

The rising demand for targeted therapies is a crucial driver as patients seek treatments with fewer side effects compared to traditional chemotherapy. Moreover, collaborations between pharmaceutical companies and biotechnology firms are accelerating the development of innovative CD47-targeting products.

There are great prospects that can be tapped into within this market, predominately the development of combination therapies. Just combining CD47 blockers with ongoing cancer treatments may offer better efficacy and improve the quality of patients’ lives.

Furthermore, as the clinical trials progress and more positive results are observed, there are likely to be opportunities for new players in the market to target niche markets in rare cancers with no available treatment options. There is also the prospect for unique therapies provided to patients depending on their unique profiles that could redefine treatment in cancer management.

Recent changes in the external environment provide an impetus for the increase of clinical trials on CD47 inhibitors, which seem to attract considerable attention from both investors and researchers.

The pipeline for CD47-targeting therapeutics is expanding, suggesting that more options will soon be available for patients. There is also a notable rise in awareness regarding the importance of cancer immunotherapy in medical communities, contributing to a more favorable regulatory environment for these therapies.

As research progresses, the potential for CD47-based treatments to significantly change outcomes for patients creates a dynamic and promising landscape within the oncology market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **CD47 Targeting Therapeutics Market Drivers**

#### Growing incidence of cancer and autoimmune diseases

The rising prevalence of cancer and autoimmune diseases has emerged as a significant driver in the CD47 Targeting Therapeutics Market Industry. As these health conditions continue to affect a considerable portion of the global population, there is an escalating demand for innovative and effective treatment options.

CD47 targeting therapeutics have shown promise in potentially enhancing the effectiveness of existing treatments, particularly in oncology. This growing incidence of complex diseases necessitates the exploration of novel therapies that can not only improve patient outcomes but also reduce the burden of disease.

The awareness and understanding of the potential benefits of CD47 targeting strategies are gradually increasing among healthcare professionals and patients alike, driving the development and commercialization of these therapeutics. Moreover, government and private organizations are investing in research and development (R) activities to further explore the applications of CD47 targeting agents, thus amplifying their role.

This surge in investment and research is believed to significantly contribute to the expected growth of the market, indicating a promising landscape for stakeholders involved in the CD47 therapeutics domain. Additionally, collaboration between pharmaceutical companies and academic institutions is fostering innovation and expediting the clinical development of these therapies.

#### Increasing research funding and investment

The CD47 Targeting Therapeutics Market Industry is experiencing a wave of investment and funding aimed at advancing research and development efforts within the sector. With governments, private investors, and venture capitalists recognizing the potential of CD47 targeting therapeutics, financial resources are being funneled into clinical trials and innovative studies.

This influx of capital is crucial for accelerating the development of new therapies, enabling researchers to explore uncharted territories in cancer treatment and beyond. The increased availability of funding not only supports the existing pipeline of CD47 targeting agents but also nurtures collaborative ventures between public and private entities, fostering an environment ripe for breakthroughs.

This dynamic investment landscape serves as a catalyst for market growth, expanding opportunities for companies to innovate and bring novel therapies to market at an expedited pace.

#### Advancements in biotechnology and pharmaceuticals

Technological advancements in biotechnology and pharmaceuticals are significantly propelling the CD47 Targeting Therapeutics Market Industry forward. Continuous innovations in drug development processes, including monoclonal antibodies and engineered therapeutics, are enhancing the efficacy of CD47 targeting agents. These advancements enable researchers to develop more precise and targeted therapies, resulting in improved treatment outcomes.

As the pharmaceutical landscape evolves, companies are increasingly leveraging these technological breakthroughs to enhance the effectiveness of existing therapies and formulate novel solutions, thereby invigorating market growth.

### **CD47 Targeting Therapeutics Market Segment Insights**

#### CD47 Targeting Therapeutics Market Therapeutic Area Insights

The CD47 Targeting Therapeutics Market is expected to reach a value of 1.6 USD Billion in 2023 and is projected to grow significantly, driven by advancements in treatment modalities and increasing demand for targeted therapies. Within this market, Therapeutic Areas play a crucial role, with Oncology emerging as a dominant segment, valued at 0.8 USD Billion in 2023 and anticipated to surge to 5.1 USD Billion by 2032.

This reflects a growing recognition of CD47's role in cancer immunotherapy. This substantial market share is reflective of the urgent need for effective cancer treatments, making it a focal point for research and development.

Autoimmune Diseases  represent another vital area, with a market valuation of 0.4 USD Billion in 2023, projected to rise to 2.8 USD Billion by 2032. The significance of targeting CD47 in this domain is underscored by the increasing prevalence of autoimmune disorders, placing pressure on healthcare systems.

Infectious Diseases, assessed at 0.3 USD Billion in 2023 and expected to expand to 1.9 USD Billion by 2032, highlights the potential of CD47 targeting therapies in addressing public health challenges such as emerging infectious pathogens.

Furthermore, Hemato-oncology, while currently valued at 0.1 USD Billion in 2023 and projected to reach 0.4 USD Billion by 2032, represents an area of interest as its growth may be fueled by the intersection of hematological malignancies and advancements in immunotherapy approaches.

The robust growth observed in these therapeutic areas exemplifies the market’s diverse applications and the opportunities that exist within the CD47 Targeting Therapeutics Market. Emerging trends in personalized medicine, together with the evolving landscape of regulatory approvals, are likely to catalyze further growth.

The rising incidence of autoimmune diseases and increased public awareness of these conditions are driving notable developments in the global market for [autoimmune disease treatments](../../../reports/autoimmune-disease-treatment-market-5586).

However, challenges such as market access and pricing pressures may impact overall market dynamics. The insights presented in the CD47 Targeting Therapeutics Market data underscore the critical role that these therapeutic areas will play in shaping the future of targeted therapies for a range of diseases, thereby influencing both market movements and health outcomes globally.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### CD47 Targeting Therapeutics Market Mechanism of Action Insights

The CD47 Targeting Therapeutics Market, valued at 1.6 billion USD in 2023, encompasses various mechanisms of action that play a crucial role in advancing therapeutic solutions. Among these, Monoclonal Antibodies are significant as they have shown promising efficacy in targeting cancer cells by blocking the CD47 signal.

Similarly, Small Molecule Inhibitors contribute greatly to the market by providing oral administration options, which streamline treatment regimens for patients. Combination Therapies are also becoming increasingly important, as they harness multiple mechanisms to enhance the overall effectiveness of treatment, showing notable potential.

These mechanisms are driving the market's growth, significantly influencing research and development efforts. The overall market is expected to reach 10.2 billion USD by 2032, showcasing a rapidly expanding landscape fueled by ongoing innovations in these mechanisms and their applications across various therapeutic areas.

The growth is propelled by rising incidences of hematologic cancers and solid tumors, further highlighting the importance of these mechanisms in shaping the future of the CD47 Targeting Therapeutics Market.

#### CD47 Targeting Therapeutics Market Route of Administration Insights

The CD47 Targeting Therapeutics Market, particularly focusing on the Route of Administration, encompasses various methods such as Intravenous, Subcutaneous, Oral, and Intramuscular administration. As of 2023, the overall market is valued at 1.6 billion USD, showcasing a robust growth trajectory anticipated to reach 10.2 billion USD by 2032.

The market growth is significantly influenced by the preference for Intravenous administration, which provides rapid delivery and higher bioavailability of therapeutics, making it a vital method in acute scenarios. Subcutaneous administration is gaining attention due to its ease of self-administration and patient compliance, appealing to long-term treatment strategies.

Oral administration presents advantages with its convenience, although the complex nature of CD47 targeting agents may limit its application. Intramuscular administration offers an alternative for certain patient populations, ensuring effective absorption and distribution. This segment reflects not only patient-centered treatment options but also highlights growing advancements.

Overall, the market exhibits an opportunity for diversification in administration routes, contributing to the evolving landscape of the CD47 Targeting Therapeutics Market industry, with evolving methodologies responding to healthcare needs.

#### CD47 Targeting Therapeutics Market End User Insights

The CD47 Targeting Therapeutics Market is experiencing notable growth, with a valuation reaching 1.6 USD billion in 2023. The end-user segment plays a critical role in this expansion, encompassing various entities that adopt these innovative therapies. Hospitals, being key players in this landscape, often lead in the adoption of CD47 targeting therapeutics, primarily due to their advanced infrastructure and access to a larger patient population.

Specialty clinics also contribute significantly, focusing on specific treatments and providing tailored care options that enhance patient outcomes. Research institutions are vital as well, driving innovation and clinical trials that validate the efficacy of these therapies, which fosters further development and acceptance.

The diverse end-user landscape reflects the versatility and growing demand for CD47 targeting therapeutics, as a decline in traditional treatments motivates the search for next-generation solutions. Market trends indicate an increasing focus on personalized medicine, evident through rising collaboration between these end users.

Overall, the CD47 Targeting Therapeutics Market revenue is poised for robust growth as these end users enhance access to life-changing treatments while advancing research to address unmet clinical needs.

#### CD47 Targeting Therapeutics Market Regional Insights

The CD47 Targeting Therapeutics Market is experiencing significant expansion, with its growth heavily influenced by regional dynamics. In 2023, North America holds the majority share, valued at 0.72 USD Billion, and is projected to rise to 4.58 USD Billion by 2032, reflecting strong investment and innovation.

Europe follows, starting at 0.48 USD Billion in 2023 and expected to reach 3.1 USD Billion by 2032, showcasing its importance due to advanced healthcare infrastructure and research capabilities. The APAC region, although starting lower at 0.32 USD Billion in 2023, is projected to grow to 2.1 USD Billion, driven by increasing demand for novel therapies.

South America and the MEA regions represent the smallest portions of the market, valued at 0.16 USD Billion and 0.12 USD Billion in 2023, respectively, but show potential for growth, with valuations reaching 1.3 USD Billion and 0.94 USD Billion by 2032.

The rising awareness of CD47 targeting therapeutics across these regions presents opportunities for market players, fostering competitive dynamics and innovation in treatment approaches. Furthermore, market growth is supported by the increasing prevalence of cancer and related disorders, enhancing the demand for effective therapies in these regions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **CD47 Targeting Therapeutics Market Key Players and Competitive Insights**

The CD47 Targeting Therapeutics Market has garnered significant attention as CD47 has emerged as a critical immune checkpoint involved in the evasion of cancer cells from the immune system. The competitive landscape is characterized by biotechnology and pharmaceutical companies striving to develop innovative therapeutics that target CD47.

This aims to facilitate enhanced anti-tumor immune responses and improve treatment outcomes for patients across various cancer types. As research progresses, collaborations between industry players and academic institutions are becoming increasingly common, aimed at accelerating the development of synergistic therapies that can combine CD47 targeting with other modalities.

This market is expected to grow significantly as a result of ongoing clinical trials and the rising demand for more effective cancer treatments.

Hutchison China MediTech has established a notable presence in the CD47 Targeting Therapeutics Market through its robust research and development initiatives focused on immuno-oncology. The company has leveraged its strong scientific expertise and innovative pipeline to advance its CD47-targeting therapies, capitalizing on the growing understanding of the role that CD47 plays in immune evasion.

Hutchison China MediTech has demonstrated significant strengths, including a well-established infrastructure for the development and commercialization of novel therapeutics, as well as strategic partnerships that bolster its position. Furthermore, the company's commitment to clinical excellence allows it to effectively navigate regulatory frameworks while providing promising therapeutic options.

Eli Lilly and Company is another key player in the CD47 Targeting Therapeutics Market, actively pursuing advancements in immuno-oncology. The company's extensive resources and strong research capabilities enable it to explore multiple avenues in developing CD47-targeting therapeutics.

Eli Lilly and Company benefits from its established brand reputation and diverse portfolio, which underpins its ability to invest in high-risk, high-reward research areas like CD47 targeting. Through collaborations with academic institutions and other biotech firms, Eli Lilly and Company aims to enhance its therapeutic offerings.

The company remains committed to addressing the complex challenges in cancer treatment by continuously expanding its research initiatives and developing cutting-edge therapies that have the potential to revolutionize cancer care.

#### Key Companies in the CD47 Targeting Therapeutics Market Include

- Hutchison China MediTech
- Eli Lilly and Company
- Gilead Sciences
- Novartis
- C4 Therapeutics
- AstraZeneca
- Amgen
- AbbVie
- Black Diamond Therapeutics
- BristolMyers Squibb
- Sorrento Therapeutics
- [Merck and Co.](https://www.merckmillipore.com/FR/en/product/Anti-CD47-Antibody-clone-C5-D5,MM_NF-MABF959)
- Trillium Therapeutics
- Janssen Biotech
- Iovance Biotherapeutics

### **CD47 Targeting Therapeutics Market Industry Developments**

Recent developments in the CD47 Targeting Therapeutics Market have unveiled significant advancements and collaborations among leading biopharmaceutical companies. Hutchison China MediTech has been actively pursuing clinical trials that aim to validate the efficacy of their CD47 inhibitors.

Eli Lilly and Company and Gilead Sciences are also deepening their investments in this sector with ongoing research into novel therapeutic applications. Early data from Novartis and C4 Therapeutics indicates promising outcomes in targeting CD47 pathways in various hematological malignancies.

Furthermore, AstraZeneca and Amgen are reportedly expanding their CD47-related research collaborations, which could lead to novel treatment options. Recent acquisitions have added momentum; for instance, AbbVie has acquired a small biotech firm focused on CD47 immunotherapies.

Companies like Black Diamond Therapeutics and Bristol-Myers Squibb have disclosed strategic partnerships aimed at enhancing their CD47-targeted therapeutic pipelines. The increasing attention on this market is driving growth, with a surge in valuations for firms like Trillium Therapeutics and Iovance Biotherapeutics.

Overall, the market is experiencing a dynamic shift as major players enhance their research and development efforts around CD47 targeting therapeutics, responding to emerging clinical data and competitive dynamics.

### **CD47 Targeting Therapeutics Market Segmentation Insights**

#### CD47 Targeting Therapeutics Market Therapeutic Area Outlook

- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Hemato-oncology

#### CD47 Targeting Therapeutics Market Mechanism of Action Outlook

- Monoclonal Antibodies
- Small Molecule Inhibitors
- Combination Therapies

#### CD47 Targeting Therapeutics Market Route of Administration Outlook

- Intravenous
- Subcutaneous
- Oral
- Intramuscular

#### CD47 Targeting Therapeutics Market End User Outlook

- Hospitals
- Specialty Clinics
- Research Institutions

#### CD47 Targeting Therapeutics Market Regional Outlook

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Increasing Cancer Prevalence

全球癌症发病率的上升是CD47靶向治疗市场的主要驱动因素。由于癌症仍然是导致死亡的主要原因，对创新治疗方案的需求正在增加。根据最近的统计数据，癌症病例预计将显著增加，估计到2040年，每年可能会有近3000万新病例。
 
这一令人担忧的趋势突显了有效疗法的紧迫性，特别是那些针对免疫逃逸机制如CD47的疗法。市场有望从这一日益增长的需求中受益，因为抑制CD47的疗法可能增强免疫系统识别和摧毁癌细胞的能力，从而为改善患者预后带来希望。

### Growing Focus on Personalized Medicine

向个性化医学的转变正在影响CD47靶向治疗市场。随着医疗保健逐渐摆脱一刀切的方法，越来越强调根据个体患者的特征量身定制治疗方案。CD47靶向疗法特别适合这一趋势，因为它们可以根据特定肿瘤特征和患者遗传信息进行定制。
 
这种个性化的方法不仅提高了治疗效果，还最小化了不良反应，使其成为肿瘤科医生的首选。市场对符合个性化医学原则的疗法的需求激增，表明CD47靶向药物的增长轨迹强劲。

### Advancements in Research and Development

持续的研究与开发进展正在推动CD47靶向治疗市场向前发展。单克隆抗体和小分子抑制剂等创新技术正在被探索，以增强CD47靶向疗法的有效性。最近的研究表明，这些疗法可以显著改善对肿瘤的免疫反应，从而导致有希望的临床试验结果。
 
对研发的投资是巨大的，每年有数十亿资金用于探索新型治疗方法。这一资金和创新的涌入可能会加速新CD47靶向药物的开发，从而扩大市场并为患者提供更多治疗选择。

### Regulatory Support for Innovative Therapies

监管机构对创新疗法的支持日益增强，这对CD47靶向治疗市场是有利的。简化的审批流程和对突破性疗法的激励措施鼓励制药公司投资于CD47靶向治疗。
 
最近建立的监管框架旨在加快有前景的疗法的开发和批准，特别是那些满足未满足医疗需求的疗法。这种支持性环境可能会促进创新，加速新CD47靶向药物进入市场，最终增强患者的治疗选择并推动市场增长。

### Collaborative Partnerships in Drug Development

制药公司、学术机构和研究组织之间的合作伙伴关系正在成为CD47靶向治疗市场的关键驱动因素。这些合作促进了知识、资源和专业知识的共享，这可以显著增强CD47靶向疗法的开发。
 
通过资源整合，合作伙伴可以进行更大规模和更全面的[临床试验](https://www.marketresearchfuture.com/reports/clinical-trials-market-7787)，从而增加成功结果的可能性。合作趋势显而易见，许多合作伙伴关系正在形成，以推动该领域的研究。这种联盟预计将加速创新的步伐，更高效地将新疗法推向市场。

## Future Outlook

CD47靶向治疗市场规模预计到2035年将达到233亿美元，年均增长率为22.89%，这得益于免疫治疗的进步和癌症发病率的增加。

**New opportunities:**

- 与现有癌症治疗的联合疗法开发。 在新兴市场扩展，提供量身定制的治疗解决方案。 投资个性化医学方法，以提高患者的治疗效果。

到2035年，该市场预计将巩固其在创新癌症疗法中的领导地位。

## Segment Insights

### 按治疗领域：肿瘤学（最大）与自身免疫疾病（增长最快）

市场在治疗领域上显示出多样化的细分，肿瘤学在CD47靶向治疗市场中占据72%的最大份额。肿瘤学主要用于癌症治疗，受益于全球癌症发病率的增加。与此同时，自身免疫疾病已成为增长最快的细分领域，受到自身免疫疾病诊断增加和针对这些复杂疾病的创新治疗管线扩展的推动。

肿瘤学（主导）与自身免疫疾病（新兴）

肿瘤学细分市场主导，特点是针对各种癌症的强大研发。靶向CD47的作用机制在增强抗肿瘤反应方面显示出希望，因此使该细分领域成为制药公司的主要关注点。相比之下，自身免疫疾病在市场中代表一个新兴领域，反映出对如[类风湿性关节炎](https://www.marketresearchfuture.com/reports/rheumatoid-arthritis-market-1658)和狼疮等疾病的认识和诊断率的提高。针对自身免疫指征的靶向治疗需求正在快速增长，这归因于未满足的医疗需求和治疗精确性的潜力。

### 按作用机制：单克隆抗体（最大）与小分子抑制剂（增长最快）

单克隆抗体在CD47靶向治疗市场中占据66%的显著份额，因其已建立的治疗有效性和安全性。它们主导市场格局，受到先进研发和持续临床试验的推动，增强了它们在肿瘤学界的可见性和接受度。另一方面，小分子抑制剂作为强有力的竞争者正在崭露头角，利用其穿透细胞并抑制调节对抗癌症免疫反应的关键通路的能力。这一动态开始吸引投资者和研究人员的关注，表明市场可能发生转变。随着医疗行业的不断发展，这两个细分市场的增长受到独特趋势和需求的影响。单克隆抗体受到对靶向治疗需求的持续推动，具有较少的副作用，巩固了它们在标准治疗方案中的地位。与此同时，小分子抑制剂的药物发现过程的快速进展正在提高它们的受欢迎程度，承诺更快的开发时间和更广泛的应用可能性。随着精准医学和个性化治疗的兴起，这两个细分市场都准备迎接令人兴奋的发展，将重新定义肿瘤学的治疗格局。

单克隆抗体（主导）与小分子抑制剂（新兴）

单克隆抗体长期以来一直是市场的支柱，因为它们在结合CD47蛋白方面具有高特异性和有效性，有效增强抗肿瘤免疫。它们在临床应用中特别成熟，提供了关于其治疗结果的强大数据。这种主导地位的特点是几个关键参与者大量投资于改进和创新，确保新疗法的稳定管线。相反，小分子抑制剂作为新兴竞争者迅速获得关注，主要是由于其可以口服给药的能力和干扰多个信号通路的潜力。这种多功能性允许开发创新的组合策略，使它们成为对抗CD47相关恶性肿瘤的有前景的未来替代方案。

### 按给药途径：静脉注射（最大）与皮下给药（增长最快）

在CD47靶向治疗市场中，各给药途径的市场份额分布多样，静脉注射（IV）目前占据63%的最大份额。这一主导地位主要归因于其快速起效和在临床环境中的广泛接受。皮下给药（SC）则正在获得关注，反映出向更少侵入性给药方法的显著转变，从而提高患者的舒适度和依从性。总体而言，这一细分市场突显了给药途径在优化治疗效果和患者体验中的重要性。给药途径细分市场的增长趋势反映出对创新输送系统的需求加大。静脉途径仍然是急性治疗的关键，而皮下途径则在慢性治疗中逐渐成为首选，受到技术进步和自我给药需求的推动。此外，口服治疗也在不断开发，以简化治疗方案。这些趋势的探索性特征表明市场格局动态，热衷于以患者为中心的方法，最终塑造了各种给药途径的增长轨迹和市场渗透。

静脉注射（主导）与皮下给药（新兴）

静脉注射（IV）给药途径因其已证明的有效性和快速的治疗作用而在市场中脱颖而出。它在医院环境中广泛受到青睐，特别是对于需要立即治疗效果的患者。与此同时，皮下（SC）途径作为一种重要的替代方案正在崭露头角，尤其是在门诊环境中，因为它允许自我给药并增加患者自主性。对SC途径的偏好源于其易用性、降低并发症风险和改善患者生活质量。随着医疗保健不断向更以患者为中心的模式发展，这两种途径体现了传统与创新治疗给药方法之间的平衡。

### 按最终用户：医院（最大）与专科诊所（增长最快）

CD47靶向治疗市场具有多样化的最终用户细分，医院占据58%的最大份额，满足大量需要先进治疗的患者。另一方面，专科诊所通过提供更个性化的治疗选择并专注于特定治疗领域，迅速获得关注，从而吸引越来越多的患者。研究机构在这个生态系统中也发挥着重要作用，尽管与医院和专科诊所相比，其规模较小，但它们为持续的临床试验和创新做出了贡献。

最终用户：医院（主导）与专科诊所（新兴）

医院被认为是市场中主导的最终用户，因为它们拥有广泛的基础设施和处理需要专业治疗的复杂病例的能力。它们通常与制药公司建立了良好的联系，促进新疗法的采用。相反，专科诊所代表了一个新兴力量，提供针对特定疾病的靶向治疗，并因其在实施创新解决方案方面的灵活性而受到认可。它们的增长受到对个性化医学、改善患者体验和优先考虑及时治疗获取的协作护理模式的需求增加的推动，使它们在不断发展的治疗格局中成为关键参与者。

## Regional Market Share Analysis

CD47靶向治疗市场正在经历显著扩张，其增长受到区域动态的强烈影响。在2023年，北美占据了大部分市场份额，估计为7.2亿美元，预计到2032年将上升至45.8亿美元，反映出强劲的投资和创新。

- 疾病控制与预防中心（CDC）报告美国每年有超过190万新癌症病例，而健康指标与评估研究所（IHME）强调北美癌症负担的增加，支持对先进免疫治疗解决方案和靶向治疗的强劲需求。

欧洲紧随其后，2023年起步于4.8亿美元，预计到2032年将达到31亿美元，展示出其因先进医疗基础设施和研究能力而重要的地位。亚太地区虽然在2023年起步较低，仅为3.2亿美元，但预计将增长至21亿美元，受到对新型疗法需求增加的推动。

- 世界卫生组织（WHO）报告称癌症是欧洲主要的死亡原因，而欧洲疾病预防控制中心（ECDC）支持30个国家的癌症监测协调，强化了对先进靶向疗法和免疫治疗创新的强劲需求。

南美和中东及非洲地区在市场中占据最小份额，2023年分别估值为1.6亿美元和1.2亿美元，但显示出增长潜力，预计到2032年估值将达到13亿美元和9.4亿美元。

这些地区对CD47靶向治疗的日益关注为市场参与者提供了机会，促进了竞争动态和治疗方法的创新。此外，市场增长受到癌症及相关疾病日益普遍的支持，增强了这些地区对有效疗法的需求。

## Competitive Benchmarking

CD47靶向治疗市场引起了显著关注，因为CD47已成为涉及癌细胞逃避免疫系统的重要免疫检查点。竞争格局的特点是生物技术和制药公司努力开发靶向CD47的创新疗法。这旨在促进增强的抗肿瘤免疫反应，并改善各种癌症类型患者的治疗结果。
 
随着研究的进展，行业参与者与学术机构之间的合作变得越来越普遍，旨在加速协同疗法的开发，这些疗法可以将CD47靶向与其他方式结合。由于正在进行的临床试验和对更有效癌症治疗的日益需求，该市场预计将显著增长。和记黄埔中国医疗科技公司通过其专注于免疫肿瘤学的强大研发举措在市场上建立了显著的存在。
 
该公司利用其强大的科学专业知识和创新管道推进其CD47靶向疗法，利用对CD47在免疫逃逸中作用的日益理解。和记黄埔中国医疗科技公司展示了显著的优势，包括建立良好的基础设施用于新型疗法的开发和商业化，以及增强其市场地位的战略合作伙伴关系。此外，该公司对临床卓越的承诺使其能够有效地应对监管框架，同时提供有前景的治疗选择。
 
礼来公司是CD47靶向治疗市场的另一个关键参与者，积极追求免疫肿瘤学的进展。该公司的广泛资源和强大的研究能力使其能够探索开发CD47靶向疗法的多种途径。礼来公司受益于其建立的品牌声誉和多样化的产品组合，这为其投资于高风险、高回报的研究领域（如CD47靶向）提供了基础。
 
通过与学术机构和其他生物技术公司的合作，礼来公司旨在增强其治疗产品。该公司致力于解决癌症治疗中的复杂挑战，通过不断扩大其研究举措和开发具有潜力的前沿疗法来应对这些挑战，这些疗法有可能彻底改变癌症护理。

## Recent News & Developments

CD47靶向治疗市场的最新发展揭示了领先生物制药公司之间的重大进展和合作。和记黄埔中国医疗科技公司一直积极进行临床试验，旨在验证其CD47抑制剂的有效性。

礼来公司和吉利德科学公司也在加大对该领域的投资，进行新型治疗应用的持续研究。来自诺华和C4治疗公司的早期数据表明，在各种血液恶性肿瘤中靶向CD47通路的结果令人鼓舞。

此外，阿斯利康和安进公司据报道正在扩大其CD47相关的研究合作，这可能会导致新治疗选择的出现。最近的收购增加了动力；例如，艾伯维收购了一家专注于CD47免疫疗法的小型生物技术公司。

像黑钻石治疗公司和百时美施贵宝公司这样的公司已披露战略合作伙伴关系，旨在增强其CD47靶向治疗管道。对该市场的关注日益增加，推动了增长，像Trillium Therapeutics和Iovance Biotherapeutics这样的公司的估值激增。

总体而言，市场正在经历动态转变，主要参与者正在增强其围绕CD47靶向治疗的研究和开发努力，以应对新兴的临床数据和竞争动态。

## Report Scope

| 市场规模 2024 | 24.13（亿美元） |
| --- | --- |
| 市场规模 2025 | 29.65（亿美元） |
| 市场规模 2035 | 233（亿美元） |
| 年均增长率（CAGR） | 22.89%（2025 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 亿美元 |
| 主要公司简介 | Forty Seven Inc（美国）、吉利德科学公司（美国）、百时美施贵宝公司（美国）、阿斯利康公司（英国）、诺华公司（瑞士）、默克公司（美国）、安进公司（美国）、CureVac AG（德国）、Zymeworks Inc（加拿大） |
| 覆盖的细分市场 | 治疗领域、作用机制、给药途径、最终用户、区域 |
| 主要市场机会 | 新兴的靶向CD47免疫疗法显示出颠覆癌症治疗范式的潜力。 |
| 主要市场动态 | 对CD47靶向治疗的兴趣上升推动生物制药公司之间的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东及非洲 |

## Frequently Asked Questions

**Q: CD47靶向治疗市场目前的市场估值是多少？**
A: 截至2024年，CD47靶向治疗市场的市场估值为24.13亿美元。

**Q: 到2035年，市场的预计规模是多少？**
A: 预计到2035年，市场估值将达到233亿美元。

**Q: 在预测期内，CD47靶向治疗市场的预期年复合增长率是多少？**
A: 预计2025年至2035年，CD47靶向治疗市场的年复合增长率为22.89%。

**Q: 哪些治疗领域预计将推动市场增长？**
A: 肿瘤学预计将主导，预计在预测期内从15亿美元增长到140亿美元。

**Q: CD47靶向治疗市场的主要作用机制是什么？**
A: 单克隆抗体预计将占主导地位，预计从9.63亿美元增长到93.3亿美元。

**Q: 给药途径如何影响市场？**
A: 静脉给药预计将从9.63亿美元增长到93.3亿美元，表明强烈的偏好。

**Q: CD47靶向治疗的主要终端用户是谁？**
A: 医院预计将保持最大的终端用户地位，从9.64亿美元增长到93.3亿美元。

**Q: CD47靶向治疗市场的领先公司有哪些？**
A: 主要参与者包括Forty Seven Inc、Gilead Sciences Inc和Bristol-Myers Squibb Company等。

**Q: 在CD47靶向治疗市场中，自身免疫疾病的增长潜力如何？**
A: 自身免疫疾病的细分市场预计将从5亿美元增长到30亿美元，表明显著的潜力。

**Q: 组合疗法与市场中其他机制相比如何？**
A: 组合疗法预计将从7.26亿美元增长到68.5亿美元，表明在市场中的竞争地位。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cd47-targeting-therapeutics-market-40260*